ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds – IMGN901 and SAR3419 – are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.
